Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
US12006370B2 · kind B2 · utility
0Cited by
97References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 22, 2021 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Mar 24, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods of depleting CD5+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD5 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.